Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $26.4252W HIGH $37.78
Volume
220.25 K
Value Traded
4.27 M
Short % Float
6.77%
+0.85%Week
+10.71%1 Month
+0.34%3 Month
+3.43%6 Month
-62.89%5 Year
+250.19%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.95 B
EPS (TTM)
8.67
P/E Ratio
3.41
Ent. Value
-1.61 B
Total Shares
65.90 M
Float Shares
49.01 M
Insiders
25.35%
Institutions
23.39%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LKFT Catalyst Timeline
Dated clinical, regulatory and corporate events for Lakefront Biotherapeutics
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lakefront Biotherapeutics
290Total events
3Upcoming
90Tier-1 (high impact)
2015 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Orphan Drug DesignationgamgertamigDesignation
FDA granted orphan drug designation to gamgertamig for pemphigus
pemphigussource ↗
●Enrollment UpdategamgertamigTrial
Phase 1b study active in Australia, New Zealand, Czech Republic, and Japan
seropositive autoimmune diseases (idiopathic myositis, Sjögren's, pemphigus vulgaris, pemphigus foliaceus)source ↗
●Trial InitiationgamgertamigTrial
Phase 1b trial in seropositive autoimmune diseases active in Australia, New Zealand, Czech Republic, Japan
seropositive autoimmune diseases (idiopathic myositis, Sjögren's, pemphigus vulgaris, pemphigus foliaceus)source ↗
●Management ChangeCorporate
Paulo Fontoura resigns from Board of Directors after appointment as Global Head of R&D at Sanofi
◆Management ChangeCorporate
Extraordinary Shareholders' Meeting (EGM) to vote on name change and share repurchase
▲Partnership / LicensegamgertamigCorporate
Collaboration Agreement with Gilead to advance T cell engager expected to close in Q2 2026
autoimmune diseasessource ↗
▲Partnership / LicensegamgertamigCorporate
Galapagos and Gilead enter binding agreement to collaborate on gamgertamig
autoimmune diseasessource ↗
●IND SubmissionGLPG5101IND
IND submission for Phase 1/2 study of GLPG5101 in the U.S.
relapsed/refractory non-Hodgkin lymphomasource ↗
●Trial InitiationGLPG5201Trial
CTA submission for Phase 2 study of GLPG5201 in Europe
chronic lymphocytic leukemia & Richter transformationsource ↗
●Protocol AmendmentGLPG5301Trial
Protocol amendment submitted for BCMA CAR-T candidate GLPG5301
relapsed/refractory multiple myelomasource ↗
▲Partnership / Licenseuza-celCorporate
Clinical collaboration with option to exclusively license Adaptimmune's uza-cel
solid tumorssource ↗
●IND SubmissionGLPG5201IND
Upcoming IND filing in the U.S. for GLPG5201
chronic lymphocytic leukemia & Richter transformationsource ↗
▼Quarterly UpdateCorporate
Revised 2023 net sales guidance for Jyseleca from 140-160 million to 100-120 million
▼Topline ReadoutClinical Data
Topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn's disease
Crohn's diseasesource ↗
▼Program DiscontinuationCorporate
Decision not to submit Marketing Authorization Application in Europe for filgotinib in Crohn's disease
Crohn's diseasesource ↗
◆Trial Initiation5101Trial
Start of dose expansion in 2023 pending regulatory approval
relapsed/refractory non-Hodgkin lymphomasource ↗
◆Trial Initiation3667Trial
Start Phase 2 with 3667 in SLE in 2023
systemic lupus erythematosussource ↗
◆Topline ReadoutJyselecaApprovedClinical Data
Topline results from DIVERSITY Phase 3 study in Crohn's disease
Crohn's diseasesource ↗
●Trial InitiationGLPG3667Trial
Start of Phase 2 study of GLPG3667 in SLE
systemic lupus erythematosussource ↗
◆EU ApprovalEx-US Regulatory
European Commission adoption following CHMP opinion on article 20 procedure
JAK inhibitorssource ↗
◆Oral PresentationCD19Presentation
Initial data from ATALANTA-1 Phase 1/2 study of CD19 CAR-T in rrNHL at ASH
relapsed/refractory non-Hodgkin lymphomasource ↗
●Trial InitiationGLPG3667Trial
First patients potentially recruited in Phase 2 program for GLPG3667 in dermatomyositis
dermatomyositissource ↗
◆CHMP Positive OpinionJyselecaApprovedEx-US Regulatory
CHMP opinion on type II variation for Jyseleca label based on MANTA data expected around year-end
ulcerative colitissource ↗
◆CHMP Positive OpinionEx-US Regulatory
CHMP opinion on article 20 pharmacovigilance procedure for all JAK inhibitors expected by year-end
JAK inhibitorssource ↗
◆Other Regulator MilestoneJyselecaApprovedEx-US Regulatory
Sobi to progress reimbursement discussions in RA and UC in Eastern and Central Europe, Greece, and Baltic countries
rheumatoid arthritis and ulcerative colitissource ↗
Past FDA Catalysts and PDUFA Decisions
How LKFT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
6
Drugs Scored
rNPV / MCap
Top Drug
Top 64%
Micro Cap(rank 421 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OM336 Small moleculeNCT07083960 | AIHA - Warm Autoimmune Hemolytic Anemia | Phase 1 | RECRUITING | 32 | Sep 1, 2027 | ||||||
| OM336 Small moleculeNCT07229144 | Sjogrens Disease | Phase 1 | RECRUITING | 39 | Mar 1, 2028 | ||||||
| GLPG3667 Small moleculeCompletedNCT05856448 | Systemic Lupus Erythematosus | Phase 2 | COMPLETED | 186 | Feb 27, 2026 | ||||||
| GLPG3667 Small moleculeCompletedNCT05695950 | Dermatomyositis | Phase 2 | COMPLETED | 40 | Apr 20, 2026 | ||||||
| GLPG3667 Small moleculeCompletedNCT04594928 | Plaque Psoriasis | Phase 1 | COMPLETED | 30 | May 4, 2021 | ||||||
| GLPG4716 Small moleculeCompletedNCT05030857 | Undisclosed | Phase 1 | COMPLETED | 77 | Nov 13, 2021 | ||||||
| GLPG0555 Small moleculeCompletedNCT01208753 | Undisclosed | Phase 1 | COMPLETED | 71 | Feb 1, 2011 | ||||||
| GLPG3121 Small moleculeCompletedNCT03899909 | Undisclosed | Phase 1 | COMPLETED | 81 | Jun 3, 2019 | ||||||
| GLPG4399 Small moleculeCompletedNCT04653467 | Undisclosed | Phase 1 | COMPLETED | 88 | Jan 10, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every LKFT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| filgotinib | rheumatoid arthritis | Phase 2b | 2015-09-28 | 877 patients; 24-week Phase 2B studies; three-fold more JAK1 selective than ABT-494; more than 700 patient-years of treatment experience; more than 500 years at the highest 200 mg doseRead More | Regulated information 25 September 2015, 16.45 CET Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis Galapagos regains all unencumbered rights to filgotinib Filgotinib is the most selective JAK1 inhibitoRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LKFT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LKFT for Q2 2026. | ||||
LKFT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LKFT ranks across every disease it competes in
Competitive Position is a premium feature
See how LKFT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLKFT News
LKFTLakefront ontvangt transparantieverklaring van Bank of America
Lakefront Biotherapeutics NV received a transparency declaration from Bank of America, indicating that the latter's stake has fallen below 10% as of October 2, 2026. This reduction is due to the disposal of voting rights and financial instruments. Bank of America now holds 8.54% of Lakefront's outstanding shares.
Read more →LKFTLakefront Receives Transparency Notification from Bank of America
Lakefront Biotherapeutics NV received a transparency notification from Bank of America, indicating that the bank's voting rights have fallen below 10% as of October 2, 2026. This change follows a disposal of voting rights and equivalent financial instruments. The notification reflects Lakefront's adherence to Belgian transparency legislation.
Read more →LKFTLakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Lakefront Biotherapeutics NV announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference, scheduled for September 15, 2026. The company will host a fireside chat at 5:35 PM ET, with a live webcast available on its website. Lakefront focuses on developing innovative therapies for serious diseases, particularly in immunology and inflammation.
Read more →LKFTLakefront presenteert op de 24e jaarlijkse Global Healthcare Conference van Morgan Stanley
Lakefront Biotherapeutics NV announced its participation in the 24th Annual Global Healthcare Conference hosted by Morgan Stanley. The company will hold a fireside chat on September 15, 2026, at 5:35 PM ET, which will be available via a live webcast. Lakefront focuses on developing a differentiated drug pipeline for patients with serious conditions.
Read more →LKFTU.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
Lakefront Biotherapeutics announced that the U.S. FDA has granted Orphan Drug Designation to gamgertamig for treating pemphigus. This designation follows previous Fast Track and Orphan Drug Designations for other autoimmune diseases. The company is expanding its clinical trials program, with studies already underway in multiple countries. Gamgertamig is viewed as a potentially transformative treatment for patients with autoimmune conditions.
Read more →LKFTAmerikaanse FDA kent weesgeneesmiddelstatus toe aan Gamgertamig voor de behandeling van Pemphigus
Lakefront Biotherapeutics announced that the FDA has granted orphan drug status to gamgertamig for the treatment of pemphigus. This designation follows previous fast track and orphan drug designations for other autoimmune conditions. The company is actively conducting clinical trials and expects to expand its study programs in 2027.
Read more →LKFTLakefront kondigt het terugtreden van Paulo Fontoura uit de Raad van Bestuur aan na zijn benoeming tot Global Head of Research & Development bij Sanofi
Lakefront Biotherapeutics announced that Dr. Paulo Fontoura has resigned from its Board of Directors following his appointment as Global Head of Research & Development at Sanofi. The company praised Fontoura for his insights during his tenure and expressed intentions to appoint a successor soon. This leadership change reflects Fontoura's career advancement in the biopharma industry.
Read more →LKFTLakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi
Lakefront Biotherapeutics announced the resignation of Dr. Paulo Fontoura from its Board of Directors following his appointment as Global Head of R&D at Sanofi. The Chair of the Board, Gino Santini, congratulated Fontoura and thanked him for his contributions. Lakefront plans to appoint a successor soon.
Read more →LKFTLakefront ontvangt transparantieverklaring van Madison Avenue Partners
Lakefront Biotherapeutics NV has received a transparency declaration from Madison Avenue Partners, indicating that the latter has exceeded the 5% threshold of voting rights as of June 15, 2026. This declaration highlights Madison Avenue Partners' growing stake in Lakefront, which now holds 5.31% of the company's shares. Lakefront is focused on developing treatments for serious conditions with unmet medical needs.
Read more →LKFTLakefront Receives Transparency Notification from Madison Avenue Partners
Lakefront Biotherapeutics NV received a transparency notification from Madison Avenue Partners, indicating that they crossed the 5% threshold of voting rights on June 15, 2026. This acquisition reflects Madison Avenue's growing interest in Lakefront, as they now hold 5.31% of the company's voting rights. The notification is part of compliance with Belgian transparency legislation.
Read more →LKFTLakefront kondigt start aan van aandeleninkoopprogramma ter waarde van € 50 miljoen
Lakefront Biotherapeutics has announced the initiation of a €50 million share buyback program, which is part of a broader strategy following a transaction with Gilead. The program allows for stock purchases until December 31, 2026, aiming to enhance shareholder value. Regular updates will be provided in compliance with regulations.
Read more →LKFTLakefront Announces Initiation of €50 Million Stock Repurchase Program
Lakefront Biotherapeutics has launched a €50 million stock repurchase program, allowing the company to buy back shares until December 31, 2026. This initiative aims to enhance shareholder value and follows a previous agreement with Gilead. The program will be executed in compliance with industry standards and will provide regular updates during its duration.
Read more →LKFTLakefront benoemt dr. Eric Hedrick tot Chief Medical Officer
Lakefront Biotherapeutics has appointed Dr. Eric Hedrick as Chief Medical Officer. This role is pivotal for the company's strategic transformation following the acquisition of Ouro Medicines. Dr. Hedrick, with 25 years of experience in drug development, will lead the development of new clinical programs, enhancing Lakefront's R&D pipeline.
Read more →LKFTLakefront Appoints Eric Hedrick, MD, as Chief Medical Officer
Lakefront Biotherapeutics has appointed Eric Hedrick, MD, as Chief Medical Officer, enhancing its leadership team following the acquisition of Ouro Medicines. Dr. Hedrick, who has over 25 years of experience in the biotech industry, will guide the development of the company's R&D pipeline. His appointment is seen as a crucial step in Lakefront's strategic transformation.
Read more →LKFTGalapagos Reports First Quarter 2026 Financial Results and Provides Business Update
Galapagos, soon to be renamed Lakefront Biotherapeutics, reported its Q1 2026 financial results, highlighting a collaboration with Gilead for a T cell engager therapy. The company anticipates a strong cash position despite expected expenditures related to the acquisition of Ouro Medicines. Management expressed optimism about the strategic direction and financial flexibility moving forward.
Read more →LKFTGalapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026 Mechelen, Belgium
Galapagos NV announced that shareholders at the Annual and Extraordinary Shareholders' Meetings held on April 28, 2026, approved all proposed resolutions. The company's CEO, Henry Gosebruch, thanked shareholders for their support and highlighted the commitment to a transformative strategy. Gino was welcomed as the new Chair of the Board, emphasizing the importance of his expertise in guiding the company. Galapagos continues to focus on bringing meaningful medicines to patients in need.
Read more →About Lakefront Biotherapeutics
HeadquartersMechelen
Founded1999
BIOPHARMAWATCH ELITE PLUS
Trade the next LKFT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime